PMID: 8942453Dec 1, 1996Paper

Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients

The American Journal of Psychiatry
D PickarJ Hsiao

Abstract

The objectives of this study were 1) to pursue the question of clozapine's striatal D2 occupancy in relation to its clinical effectiveness; 2) to investigate the relation between schizophrenic symptoms, clozapine blood levels, and estimated D2 occupancy during clinically stable and unstable conditions; and 3) to examine long-term stability in D2 occupancy. Specific binding of the D2 radioligand [123I]benzamide ([123I]IBZM) was studied with single photon emission computed tomography in 13 patients with schizophrenia when they were clinically stable during chronic clozapine treatment, after clozapine dose reduction of > or = 50%, and in a subgroup (N = 7) after restabilization on clozapine regimens. Clozapine's estimated D2 occupancy was based on comparison with values from drug-free normal subjects. A wide range of estimated D2 occupancies (18% to > or = 80%) were associated with sustained, favorable response to clozapine without correlation with residual symptoms. Clozapine blood levels were negatively related to [123I]IBZM specific binding. Acute dose reduction was associated with predicted worsening in positive and negative symptoms and increases in [123I]IBZM specific binding. Independent of clozapine blood level, patients w...Continue Reading

Citations

Jan 2, 2003·Annals of Nuclear Medicine·W Gordon Frankle, Marc Laruelle
Dec 8, 2010·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Farhat BatoolDarakhshan Jabeen Haleem
Apr 1, 2015·Journal of the Chinese Medical Association : JCMA·Chen-Chia LanYing-Sheue Chen
Jan 12, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anissa Abi-Dargham, Marc Laruelle
Apr 29, 1998·The Psychiatric Clinics of North America·R J McClureJ W Pettegrew
Feb 24, 2009·NeuroImage·Ana M CatafauUNKNOWN Barcelona Clinical Imaging in Psychiatry Group
Feb 23, 2010·Biological Psychiatry·Thomas W WeickertDaniel R Weinberger
Jul 20, 2011·Journal of Psychopharmacology·Marise MachielsenInez Myin-Germeys
Feb 18, 2005·Psychopharmacology·Carmen Chung, Gary Remington
Mar 1, 2008·Journal of Psychopharmacology·A M CatafauUNKNOWN Barcelona Clinical Imaging in Psychiatry Group
Sep 2, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Marie-Bernadette AssiéAdrian Newman-Tancredi
Jun 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Thomas J RaedlerDaniel R Weinberger
Jul 17, 2001·Nuclear Medicine Communications·L S Pilowsky
Feb 19, 2013·Psychopharmacology·Takefumi SuzukiDavid Mamo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here